TG Therapeutics, Inc. (NASDAQ: TGTX) Starts Presentation at 29th Annual Roth Conference
TG Therapeutics (NASDAQ: TGTX) is a biopharmaceutical company that focuses on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases primarily in the United States. The company develops TG-1101 (ublituximab), a novel glycol engineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. For more information, visit the company’s website at www.tgtherapeutics.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services…







